COVID-19
COVID-19 vaccines: under evaluation
The European Medicines Agency (EMA) is evaluating potential COVID-19 vaccines to enable the distribution of promising vaccines in the European Union (EU) as soon as possible.
EMA’s CHMP is evaluating marketing authorisation applications (which may be for conditional marketing authorisation) for the following COVID-19 vaccines:
| Treatment | Applicant | Start of marketing authorisation evaluation | More information |
|---|---|---|---|
| Skycovion | SK Chemicals GmbH | 18/08/2022 | Latest news |
| Bimervax (previously COVID-19 Vaccine HIPRA) | HIPRA Human Health S.L.U. | 21/03/2023 |
EMA's Committee for Medicinal Products for Human Use (CHMP) is evaluating the following COVID-19 vaccines under rolling review:
| Vaccine | Vaccine developer | Start of rolling review | More information |
|---|---|---|---|
| Sputnik V, Gam-COVID-Vac | Russia’s Gamaleya National Centre of Epidemiology and Microbiology | 04/03/2021 | EMA starts rolling review of the Sputnik V COVID-19 vaccine |
| COVID-19 Vaccine (Vero Cell) Inactivated | Sinovac Life Sciences Co., Ltd | 04/05/2021 | EMA starts rolling review of COVID-19 Vaccine (Vero Cell) Inactivated |
For additional information on the expedited evaluation procedure EMA is applying for COVID-19 vaccines, including the rolling review, see:
Vaccine developers have withdrawn the following COVID-19 vaccines from the rolling review process:
| Vaccine | Vaccine developer | Key milestones | More information |
|---|---|---|---|
| CVnCoV | CureVac AG | Rolling review started: 12/02/2021 Withdrawn from rolling review: 12/10/2021 |